JP2025515996A5 - - Google Patents
Info
- Publication number
- JP2025515996A5 JP2025515996A5 JP2024560406A JP2024560406A JP2025515996A5 JP 2025515996 A5 JP2025515996 A5 JP 2025515996A5 JP 2024560406 A JP2024560406 A JP 2024560406A JP 2024560406 A JP2024560406 A JP 2024560406A JP 2025515996 A5 JP2025515996 A5 JP 2025515996A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nucleic acid
- base sequence
- strand comprises
- acid base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263330797P | 2022-04-14 | 2022-04-14 | |
| US63/330,797 | 2022-04-14 | ||
| PCT/US2023/065812 WO2023201362A2 (en) | 2022-04-14 | 2023-04-14 | Fn3 domain-sirna conjugates with enzyme replacement therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025515996A JP2025515996A (ja) | 2025-05-23 |
| JP2025515996A5 true JP2025515996A5 (enExample) | 2026-04-20 |
Family
ID=88330423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024560406A Pending JP2025515996A (ja) | 2022-04-14 | 2023-04-14 | 酵素補充療法を用いたＦＮ３ドメイン－ｓｉＲＮＡコンジュゲート |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240043844A1 (enExample) |
| EP (1) | EP4507702A2 (enExample) |
| JP (1) | JP2025515996A (enExample) |
| KR (1) | KR20250024745A (enExample) |
| CN (1) | CN119604311A (enExample) |
| AU (1) | AU2023252976A1 (enExample) |
| CA (1) | CA3248570A1 (enExample) |
| IL (1) | IL316071A (enExample) |
| WO (1) | WO2023201362A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119119240A (zh) | 2019-10-14 | 2024-12-13 | Aro生物疗法公司 | 结合cd71的纤维粘连蛋白iii型结构域 |
| CA3214552A1 (en) | 2021-04-14 | 2022-10-20 | Russell C. Addis | Cd71 binding fibronectin type iii domains |
| EP4323008A4 (en) | 2021-04-14 | 2026-02-25 | Aro Biotherapeutics Company | FN3-ARNSI DOMAIN CONJUGATES AND THEIR USES |
| WO2025231388A1 (en) * | 2024-05-03 | 2025-11-06 | Aro Biotherapeutics Company | Methods and compositions for treating pompe disease |
| WO2025245474A1 (en) * | 2024-05-23 | 2025-11-27 | Aro Biotherapeutics Company | Formulations comprising fn3-sirna conjugates and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005072057A2 (en) * | 2004-01-30 | 2005-08-11 | Quark Biotech, Inc. | Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases |
| EA201001734A1 (ru) * | 2008-05-02 | 2011-10-31 | Новартис Аг | Улучшенные связывающие молекулы на основе фибронектина и их применение |
| US11781138B2 (en) * | 2019-10-14 | 2023-10-10 | Aro Biotherapeutics Company | FN3 domain-siRNA conjugates and uses thereof |
| WO2021226107A1 (en) * | 2020-05-05 | 2021-11-11 | Avidity Biosciences, Inc. | Compositions and methods of treating pompe disease |
| EP4323008A4 (en) * | 2021-04-14 | 2026-02-25 | Aro Biotherapeutics Company | FN3-ARNSI DOMAIN CONJUGATES AND THEIR USES |
-
2023
- 2023-04-14 CN CN202380046048.3A patent/CN119604311A/zh active Pending
- 2023-04-14 EP EP23786463.2A patent/EP4507702A2/en active Pending
- 2023-04-14 CA CA3248570A patent/CA3248570A1/en active Pending
- 2023-04-14 WO PCT/US2023/065812 patent/WO2023201362A2/en not_active Ceased
- 2023-04-14 KR KR1020247036275A patent/KR20250024745A/ko active Pending
- 2023-04-14 JP JP2024560406A patent/JP2025515996A/ja active Pending
- 2023-04-14 AU AU2023252976A patent/AU2023252976A1/en active Pending
- 2023-04-14 IL IL316071A patent/IL316071A/en unknown
- 2023-04-14 US US18/301,036 patent/US20240043844A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025515996A5 (enExample) | ||
| Lang et al. | Coronavirus hemagglutinin-esterase and spike proteins coevolve for functional balance and optimal virion avidity | |
| Chen et al. | Gene transfer with poly-melittin peptides | |
| JP2024514266A5 (enExample) | ||
| Rasmussen et al. | Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog | |
| CN109803977A (zh) | 核酸产品及其施用方法 | |
| JP2020508685A5 (enExample) | ||
| ES2804594T3 (es) | Reticuladores químicos | |
| Manjunath et al. | Mammalian proteome expansion by stop codon readthrough | |
| Daum et al. | Self-assembly of the general membrane-remodeling protein PVAP into sevenfold virus-associated pyramids | |
| JP2010516758A5 (enExample) | ||
| KR20200081487A (ko) | 단백질 조작된 세포외 소포 | |
| EP4428232A1 (en) | Isolated cas13 protein and use thereof | |
| CA2825023A1 (en) | Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes | |
| CN113150084B (zh) | 一种纳米化的冠状病毒抗原及其应用 | |
| El Cheikh et al. | Design of potent mannose 6‐phosphate analogues for the functionalization of lysosomal enzymes to improve the treatment of pompe disease | |
| JP7729842B2 (ja) | ｒｈＦＧＦ２１融合タンパク質、ｒｈＦＧＦ２１融合タンパク質をコードするポリヌクレオチド、ｒｈＦＧＦ２１融合タンパク質を含有する組成物、及びｒｈＦＧＦ２１融合タンパク質の使用 | |
| Tomanin et al. | Gene therapy approaches for lysosomal storage disorders, a good model for the treatment of mendelian diseases | |
| Marcus et al. | Replacement of the C6ORF66 assembly factor (NDUFAF4) restores complex I activity in patient cells | |
| Kormos et al. | Binding site analysis of cellulose binding domain CBDN1 from endoglucanse C of Cellulomonas fimi by site-directed mutagenesis | |
| Sikriwal et al. | An insertion in loop L7 of human eosinophil‐derived neurotoxin is crucial for its antiviral activity | |
| Antcheva et al. | Effects of positively selected sequence variations in human and Macaca fascicularis β-defensins 2 on antimicrobial activity | |
| Xiang et al. | Targeted delivery of large fusion protein into hippocampal neurons by systemic administration | |
| Kurita et al. | Identification of a region of Bacillus subtilis Ffh, a homologue of mammalian SRP54 protein, that is essential for binding to small cytoplasmic RNA | |
| Wang et al. | Emerging landscape of supercharged proteins and peptides for drug delivery |